Current Protein Identity:P00746 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
1BIO HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR Deposited 1998-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded SOA ISATOIC ANHYDRIDE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4;pH 6.4
Resolution 1.50 Å R-free 0.191
1DFP FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE Deposited 1997-02-18 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 26–253(228 aa)
Chain B 26–253(228 aa)
Not recorded DFP DIISOPROPYL PHOSPHONATE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.8;INHIBITED PROTEIN WAS CRYSTALLIZED FROM 12-16% PEG 6000 AND 0.2 M NACL,50MM MES BUFFER, PH=5.6-5.8.
Resolution 2.40 Å R-free 0.228
1DIC STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D Deposited 1998-07-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded DIC 3,4-DICHLOROISOCOUMARIN × 1 O OXYGEN ATOM × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.6;pH 5.6
Resolution 1.80 Å R-free 0.251
1DST MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY Deposited 1995-09-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Mutation:S94Y, T214S, S215W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8;pH 6.8
Resolution 2.00 Å R-free 0.213
1DSU HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME Deposited 1995-09-15 Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 26–253(228 aa)
Chain B 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.203
1FDP PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D Deposited 1998-12-03 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 19–253(235 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;298 K;CRYSTALLIZATION CONDITIONS: THE RESERVOIR SOLUTION CONTAINED 10-12% PEG-6000 AND 30MM MES (PH5.2). THE DROPS CONTAINED EQUAL VOLUME OF RESERVOIR SOLUTION AND PROTEIN SOLUTION (10MG/ML), VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.251
1FDP PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D Deposited 1998-12-03 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 19–253(235 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;298 K;CRYSTALLIZATION CONDITIONS: THE RESERVOIR SOLUTION CONTAINED 10-12% PEG-6000 AND 30MM MES (PH5.2). THE DROPS CONTAINED EQUAL VOLUME OF RESERVOIR SOLUTION AND PROTEIN SOLUTION (10MG/ML), VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.251
1FDP PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D Deposited 1998-12-03 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 19–253(235 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;298 K;CRYSTALLIZATION CONDITIONS: THE RESERVOIR SOLUTION CONTAINED 10-12% PEG-6000 AND 30MM MES (PH5.2). THE DROPS CONTAINED EQUAL VOLUME OF RESERVOIR SOLUTION AND PROTEIN SOLUTION (10MG/ML), VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.251
1FDP PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D Deposited 1998-12-03 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 19–253(235 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.2;298 K;CRYSTALLIZATION CONDITIONS: THE RESERVOIR SOLUTION CONTAINED 10-12% PEG-6000 AND 30MM MES (PH5.2). THE DROPS CONTAINED EQUAL VOLUME OF RESERVOIR SOLUTION AND PROTEIN SOLUTION (10MG/ML), VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.251
1HFD HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM Deposited 1998-06-18 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.4;pH 5.4
Resolution 2.30 Å R-free 0.216
2XW9 Crystal Structure of Complement Factor D mutant S183A Deposited 2010-11-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Mutation:YES GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6;pH 6.0
Resolution 1.20 Å R-free 0.176
2XWA Crystal Structure of Complement Factor D Mutant R202A Deposited 2010-11-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Mutation:YES GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6;pH 6.0
Resolution 2.80 Å R-free 0.283
2XWA Crystal Structure of Complement Factor D Mutant R202A Deposited 2010-11-01 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa)
Mutation:YES GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6;pH 6.0
Resolution 2.80 Å R-free 0.283
2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain J 26–253(228 aa)
Mutation:YES MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.7;PH 7.7
Resolution 3.49 Å R-free 0.244
2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 Assembly 2 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain I 26–253(228 aa)
Mutation:YES MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.7;PH 7.7
Resolution 3.49 Å R-free 0.244
2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 Assembly 3 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain J 26–253(228 aa)
Mutation:YES MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.7;PH 7.7
Resolution 3.49 Å R-free 0.244
2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 Assembly 4 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain I 26–253(228 aa)
Mutation:YES MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.7;PH 7.7
Resolution 3.49 Å R-free 0.244
4CBN Crystal structure of Complement Factor D mutant R202A after conventional refinement Deposited 2013-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa) Fragment:RESIDUES 26-253
Mutation:YES GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15% PEG 6000, 50 MM MES/NAOH, PH 6.0
Resolution 1.80 Å R-free 0.219
4CBN Crystal structure of Complement Factor D mutant R202A after conventional refinement Deposited 2013-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa) Fragment:RESIDUES 26-253
Mutation:YES GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 15% PEG 6000, 50 MM MES/NAOH, PH 6.0
Resolution 1.80 Å R-free 0.219
4CBO Crystal structure of Complement Factor D mutant R202A after ensemble refinement Deposited 2013-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa) Fragment:RESIDUES 26-253
Mutation:YES GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15% PEG 6000, 50 MM MES/NAOH PH 6.0
Resolution 1.80 Å R-free 0.212
4CBO Crystal structure of Complement Factor D mutant R202A after ensemble refinement Deposited 2013-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa) Fragment:RESIDUES 26-253
Mutation:YES GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15% PEG 6000, 50 MM MES/NAOH PH 6.0
Resolution 1.80 Å R-free 0.212
4D9R Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D Deposited 2012-01-11 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;0.1 M Tris-HCl, 0.02 M NH4PO4, MPD 50.0% v/v, 0.01 M hexamine cobalt (III) chloride, pH 8.5, vapor diffusion, hanging drop, temperature 277K
Resolution 2.42 Å R-free 0.251
4D9R Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D Deposited 2012-01-11 Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain B 26–253(228 aa)
Not recorded CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 8.5;277 K;0.1 M Tris-HCl, 0.02 M NH4PO4, MPD 50.0% v/v, 0.01 M hexamine cobalt (III) chloride, pH 8.5, vapor diffusion, hanging drop, temperature 277K
Resolution 2.42 Å R-free 0.251
5FBE COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2 Deposited 2015-12-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa) Fragment:UNP residues 26-253
Not recorded GOL GLYCEROL × 1 5W5 methyl 2-[[[(2~{S})-2-[[3-(trifluoromethyloxy)phenyl]carbamoyl]pyrrolidin-1-yl]carbonylamino]methyl]benzoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;1 MICROLITER PROTEIN SOLUTION WAS MIXED WITH 1 MICROLITER RESERVOIR SOLUTION. PROTEIN SOLUTION: 18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl; RESERVOIR SOLUTION: 22% PEG3350, 100 mM HEPES pH 7.5; SOAKING AND CRYO: ADDITION of 10 mM COMPOUND2 for 45 min FOLLOWED by the ADDITION OF 0.5 MICROLITER GLYCEROL AND FLASH FREEZING IN LIQUIT NITROGEN.
Resolution 1.43 Å R-free 0.188
5FBI COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3b Deposited 2015-12-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 5WD 3-[(2-aminocarbonyl-1~{H}-indol-5-yl)oxymethyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;1 Microliter of protein solution was mixed with 1 microliter of reservoir solution. Protein solution: 18.3 mg/ml factor D, 10 mM Tris pH 7.0, 100 mM sodium chloride; Reservoir solution: 22% PEG3350, 100 mM HEPES pH 7.5; Soaking and cryo: 0.5 ul 100 mM compound 3b in 90% DMSO was added to the crystal containing drop and incubated for 45 min followed by the addition of 0.5 ul glyerol and flash freezing in liquid nitrogen.
Resolution 1.47 Å R-free 0.196
5FCK COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5 Deposited 2015-12-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded 5WC 1-[2-[(1~{R},3~{S},5~{R})-3-[[(1~{R})-1-(3-chloranyl-2-fluoranyl-phenyl)ethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxidanylidene-ethyl]pyrazolo[3,4-c]pyridine-3-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;1 uL FD solution (18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl) was mixed with 1 uL reservoir solution (25% PEG3350, 100 mM TRIS pH 8.0) and equilibrated against 1 mL reservoir solution.
Resolution 1.86 Å R-free 0.237
5MT0 COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR Deposited 2017-01-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded QJS 5-fluoranyl-3-[[(1~{S},2~{S})-2-phenylcyclopropyl]carbonylamino]-1~{H}-indole-2-carboxylic acid × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM BIS-TRIS pH 6.5
Resolution 1.29 Å R-free 0.196
5MT4 COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR Deposited 2017-01-06 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded M7O 2-[(phenylmethyl)carbamoylamino]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;26% PEGME2000, 100mM Bis-Tris pH 6.5
Resolution 1.65 Å R-free 0.239
5NAR Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] Deposited 2017-02-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded SO4 SULFATE ION × 1 8RW (2~{S})-~{N}1-(1-aminocarbonylindol-3-yl)-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;MM NACL, 0.5MM NVP-BVT244-NX-1 + 1 UL RESERVOIR SOLUTION
Resolution 1.55 Å R-free 0.231
5NAT Complement factor D in complex with the inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] Deposited 2017-02-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded GOL GLYCEROL × 2 8RT (2~{S})-~{N}1-(1-methylindol-3-yl)-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;MM NACL + 1 UL RESERVOIR SOLUTION
Resolution 1.17 Å
5NAW Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide] Deposited 2017-02-28 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded 8RZ (1~{R},3~{S},5~{R})-~{N}2-(1-aminocarbonylindol-3-yl)-~{N}3-[3-(trifluoromethyloxy)phenyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;27% PEG 3350 100 mM HEPES pH 7.5
Resolution 1.25 Å R-free 0.178
5NB6 Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] Deposited 2017-03-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded 8S2 (2~{S},4~{S})-~{N}1-(1-aminocarbonylindol-3-yl)-4-azanyl-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;22% PEG3350, 0.1 M HEPES pH 7.5, 50 mM NaCl
Resolution 1.75 Å R-free 0.297
5NB7 Complement factor D Deposited 2017-03-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded DMS DIMETHYL SULFOXIDE × 2 8NQ 1-[2-[(1~{R},3~{S},5~{R})-3-[(6-bromanylpyridin-2-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxidanylidene-ethyl]indazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;298 K;22% PEG 3350, 0.1 m HEPES pH 7.5, 50 mM NaCl
Resolution 1.33 Å R-free 0.196
5NBA Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] Deposited 2017-03-01 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded 8S5 (2~{S},4~{R})-~{N}1-(1-aminocarbonylindol-3-yl)-4-fluoranyl-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;23% PEG 3350, 0.1 M HEPES pH 7.5, 50 mM NaCl
Resolution 1.87 Å R-free 0.260
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain F 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCA Complement Factor D inhibited with JH3 Deposited 2016-09-14 Assembly 7 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain G 26–253(228 aa) Fragment:residues 26-253
Not recorded J55 1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 8.5;293 K;0.1 M Tris-HCl pH 8.5, 15% PEG 20000
Resolution 3.15 Å R-free 0.264
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain F 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
5TCC Complement Factor D inhibited with JH4 Deposited 2016-09-14 Assembly 7 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain G 26–253(228 aa) Fragment:residues 26-253
Not recorded J56 (2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.1 M MES pH 6.5 and 25% PEG 8000
Resolution 3.37 Å R-free 0.260
6FTY COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 5 Deposited 2018-02-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E7H 4-[[(5~{S},7~{R})-3-azanyl-1-adamantyl]carbonylamino]-1~{H}-indole-2-carboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;295 K;PEG 3350, 100 mM HEPES pH 7.5
Resolution 1.67 Å R-free 0.214
6FTZ COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6 Deposited 2018-02-26 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E7E ~{N}4-[3-(aminomethyl)phenyl]-1~{H}-indole-2,4-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;295 K;PEG3350, 100 mM HEPES pH 7.5
Resolution 1.67 Å R-free 0.220
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUG Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain F 26–253(228 aa)
Not recorded E85 3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5
Resolution 2.21 Å R-free 0.259
6FUH Complement factor D in complex with the inhibitor (4-((3-(aminomethyl)phenyl)amino)quinazolin-2-yl)-L-valine Deposited 2018-02-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E88 (2~{S})-2-[[4-[[3-(aminomethyl)phenyl]amino]quinazolin-2-yl]amino]-3-methyl-butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;25% PEG3350, 100 mM TRIS pH 8.5, 200 mM NH4SO2, 2 mM inhibitor
Resolution 1.37 Å R-free 0.180
6FUI Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol Deposited 2018-02-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E7W (1~{R},2~{S})-2-[[4-[[3-(aminomethyl)phenyl]amino]quinazolin-2-yl]amino]cyclohexane-1-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5
Resolution 1.38 Å R-free 0.198
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E8B ~{N}-[3-[3-(aminomethyl)phenyl]phenyl]-3-methyl-butanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa)
Not recorded E8B ~{N}-[3-[3-(aminomethyl)phenyl]phenyl]-3-methyl-butanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 26–253(228 aa)
Not recorded E8B ~{N}-[3-[3-(aminomethyl)phenyl]phenyl]-3-methyl-butanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUJ Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide Deposited 2018-02-27 Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain F 26–253(228 aa)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor
Resolution 2.25 Å R-free 0.244
6FUT Complement factor D in complex with the inhibitor (S)-3'-(aminomethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-3-carboxamide Deposited 2018-02-27 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded E82 3-[3-(aminomethyl)phenyl]-~{N}-[(1~{S})-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide × 1 SIN SUCCINIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;22-25% PEG3350, 100 mM HEPES pH 7.5
Resolution 1.50 Å R-free 0.184
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain E 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMR Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid Deposited 2019-02-08 Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain F 2–253(252 aa)
Not recorded J6T 2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;30% PEG MME 2000, 0.1M sodium thiocyanate
Resolution 2.00 Å R-free 0.256
6QMT Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid Deposited 2019-02-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 2–253(252 aa)
Not recorded J7B 2-[2-[[3-[3-(aminomethyl)phenyl]phenyl]carbonylamino]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;25% PEGME 3350, 100 mM Bis-Tris pH 5.5
Resolution 1.80 Å R-free 0.231
6QMT Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid Deposited 2019-02-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 2–253(252 aa)
Not recorded J7B 2-[2-[[3-[3-(aminomethyl)phenyl]phenyl]carbonylamino]phenyl]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;25% PEGME 3350, 100 mM Bis-Tris pH 5.5
Resolution 1.80 Å R-free 0.231
6VMJ Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain Z 26–253(228 aa)
Not recorded CIT CITRIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1 M sodium cacodylate pH 6.5, 1 M sodium citrate
Resolution 2.95 Å R-free 0.265
6VMJ Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain Y 26–253(228 aa)
Not recorded CIT CITRIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1 M sodium cacodylate pH 6.5, 1 M sodium citrate
Resolution 2.95 Å R-free 0.265
6VMJ Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain X 26–253(228 aa)
Not recorded CIT CITRIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1 M sodium cacodylate pH 6.5, 1 M sodium citrate
Resolution 2.95 Å R-free 0.265
6VMJ Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 4 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain W 26–253(228 aa)
Not recorded CIT CITRIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;0.1 M sodium cacodylate pH 6.5, 1 M sodium citrate
Resolution 2.95 Å R-free 0.265
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain W 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 10 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain d 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 11 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain g 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 12 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain j 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 13 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain m 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 14 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain p 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 15 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain s 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 16 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain v 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain C 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain F 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 4 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain I 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 5 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain N 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 6 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain Q 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 7 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain T 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 8 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain X 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
6VMK Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12 Deposited 2020-01-28 Assembly 9 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain a 26–253(228 aa)
Not recorded GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;0.1 M sodium citrate pH 5.0, 8% PEG 8000
Resolution 3.01 Å R-free 0.215
8D95 Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-09 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded QIE N-(6-bromopyridin-2-yl)-1-[(3-cyanophenyl)acetyl]-L-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;300 K;PEG 6k
Resolution 2.17 Å R-free 0.263
8DEA Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-20 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded R7X 1-[(3-acetylphenyl)acetyl]-N-(6-bromopyridin-2-yl)-L-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;293 K;peg4k 25% , 0.1M MES 5.8 buffer
Resolution 2.21 Å R-free 0.300
8DEA Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-20 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 26–253(228 aa)
Not recorded R7X 1-[(3-acetylphenyl)acetyl]-N-(6-bromopyridin-2-yl)-L-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;293 K;peg4k 25% , 0.1M MES 5.8 buffer
Resolution 2.21 Å R-free 0.300
8DEA Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-20 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 26–253(228 aa)
Not recorded R7X 1-[(3-acetylphenyl)acetyl]-N-(6-bromopyridin-2-yl)-L-prolinamide × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;293 K;peg4k 25% , 0.1M MES 5.8 buffer
Resolution 2.21 Å R-free 0.300
8DEA Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-20 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 26–253(228 aa)
Not recorded R7X 1-[(3-acetylphenyl)acetyl]-N-(6-bromopyridin-2-yl)-L-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;293 K;peg4k 25% , 0.1M MES 5.8 buffer
Resolution 2.21 Å R-free 0.300
8DG6 Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors Deposited 2022-06-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 26–253(228 aa)
Not recorded S7X 1-{2-[(2S)-2-{[(3-chloro-2-fluorophenyl)methyl]carbamoyl}pyrrolidin-1-yl]-2-oxoethyl}-1H-indazole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 5.8;300 K;peg4k 20-30%
Resolution 1.99 Å R-free 0.251